Nilay Thakar
Principal at ARCH Venture Partners
Cambridge, Massachusetts
Overview
Work Experience
Principal
2017 - Current
ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Co-Founder and Head of BD
2021
Board Observer
2023
Board Observer
2021
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Raised $230,600,000.00 from TCG Crossover, ArrowMark Partners, Ally Bridge Group, Logos Capital, Tao Capital Partners, ARCH Venture Partners, Tekla Capital Management, Surveyor Capital, Deep Track Capital and Vertex Pharmaceuticals.
Board Observer
2022
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Raised $119,000,000.00 from Polaris Partners, Cornell University, Droia Ventures, Eli Lilly, Catalio Capital Management, ARCH Venture Partners, Vida Ventures and Meyer Ventures.
Board Observer
2022
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound.
Raised $60,750,000.00 from Eli Lilly & Company Foundation, Medical Excellence Capital, ARCH Venture Partners, Johnson & Johnson Innovation – JJDC, Foothill Ventures, Alexandria Venture Investments, Wilson Sonsini Goodrich & Rosati, Formic Ventures, Illumina Ventures and Lifespan Investments.
Board Observer
2023 - 2025
Board Observer
2022 - 2025
HC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
Raised $40,000,000.00 from ARCH Venture Partners, 8VC, Panacea Venture, Taiho Ventures, Takeda Ventures, ARCH Venture Partners, 8VC and Takeda Ventures.
Committee Member - Industry
2019 - 2023
International Society for Stem Cell Research is an organization serving the stem cell research industry.
General Manager - Stem Cells Ltd
2014 - 2016